The Uncapped Diagnostic Price Tag
A critical concern raised by a parliamentary standing committee is the conspicuous absence of any national price regulation for essential diagnostic, scanning,
and imaging services. While individual states might have implemented temporary price caps for specific tests, such as RT-PCR during the pandemic, a unified, nationwide policy for these crucial medical services is notably lacking. This regulatory void allows for a wide disparity in charges across different facilities, ultimately placing a substantial financial burden on patients who are already navigating the complexities of treatment. The committee has strongly urged both the Department of Pharmaceuticals and the Ministry of Health to collaborate and establish a uniform pricing framework to ensure greater predictability and affordability for these vital healthcare components.
Medical Devices: A Regulatory Oversight
The parliamentary panel has strongly advocated for the establishment of a dedicated, independent regulatory body specifically for medical devices. The current system, which largely categorizes medical devices under regulations designed for pharmaceuticals, is deemed insufficient to address the unique complexities and rapid advancements within the medical device sector. This pharmaceutical-centric approach, the committee argues, not only fails to adequately accommodate high-end and innovative equipment but also potentially stifles investment and growth within the domestic medical device industry. Drawing parallels with the successful model of the Food Safety and Standards Authority of India (FSSAI), the committee suggests a similar independent structure could foster a more effective and appropriate regulatory environment for medical devices.
Insurance Coverage Gaps
Even with government-backed healthcare initiatives like Ayushman Bharat, patients frequently encounter substantial out-of-pocket expenses for essential medical devices and procedures. The parliamentary committee's report highlights that certain high-value medical devices are often not accessible through subsidized government channels, forcing patients to purchase them independently. Furthermore, the reimbursement rates under the Ayushman Bharat scheme are described as outdated, failing to reflect current market realities. For instance, procedures like cardiac catheterisation are only partially covered, leaving patients to shoulder the remaining costs. This issue is particularly acute for high-cost items like valves and aortic stents, where low package rates under the scheme mean patients bear a significant financial burden. The committee's recommendations include a timely review and revision of package rates under Ayushman Bharat, especially for complex procedures in cardiology, neurosurgery, and interventional radiology.
Industry Reforms and Consumer Protection
Beyond pricing and coverage, the committee also addressed broader industry reforms and consumer protection. They supported industry calls for a transition from criminal penalties for minor procedural errors to a graded penalty system, aiming to reduce the disproportionate impact on businesses. To bolster domestic manufacturing, the panel suggested increasing import duties on certain devices while also proposing measures to streamline licensing processes, reduce the financial strain of clinical trials, and implement a 'deemed approval' pathway for devices already certified by reputable international regulators. A significant concern was also raised regarding the current practice of routing recovered overcharges to the government exchequer instead of compensating affected consumers. The committee emphasized the need for stronger enforcement mechanisms to prevent overpricing at the source, ensuring that cost savings directly benefit patients.
